RxDoctor Payments Data

Adam Ehrlich

Gastroenterology · Philadelphia, PANPI 1215197371

Payments from drug & device makers

$120,193in general payments, 2019–2025

Across 128 payments — averaging $939.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$30K
  • Johnson & Johnson$25K
  • Lilly USA, LLC$14K
  • Eli Lilly$13K
  • Janssen Scientific Affairs, LLC$12K
  • E.r. Squibb & Sons, L.L.C.$11K
  • plus $14K from 6 others

What the payments were for

  • Consulting fees$34,99530%
  • Speaking & faculty fees$74,90664%
  • Travel & lodging$4,5914%
  • Food & beverage$2,8522%
  • Education$940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie21$30,381
Johnson & Johnson31$24,969
Lilly USA, LLC28$14,233
Eli Lilly19$13,104
Janssen Scientific Affairs, LLC5$12,033
E.r. Squibb & Sons, L.L.C.9$11,499
Pfizer2$6,600
Aimmune Therapeutics, Inc.3$4,038
Janssen Research & Development, LLC4$2,878
Bristol Myers Squibb4$420
Concordia Pharmaceuticals Inc.1$22
ERBE USA Inc1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$120,193 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,548
Medicare patients
175
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab54$1,472,970
EntyvioVedolizumab13$111,990
XeljanzTofacitinib Citrate14$72,878
LinzessLinaclotide34$17,930
Mesalamine32$15,700
Mesalamine ErMesalamine32$2,353
Omeprazole147$2,037
Lubiprostone13$1,069
Dicyclomine Hcl33$897
Pantoprazole Sodium78$749
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$473
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl21$345
LoperamideLoperamide Hcl12$287
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl16$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$24,969$1,472,97054 claims
PfizerXeljanz$6,600$72,87814 claims
AbbVieLinzess$30,381$17,93034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →